“We have the FDA attempting to move forward a promising new treatment while the DEA is doing everything they can to obstruct its development.”
By Jack Gorsline, Psychedelic State(s) of America
Just one week after a historic public hearing on the future utility of psychedelic drugs at the Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland, the Drug Enforcement Administration (DEA) is moving in the opposite direction.
On Wednesday, 2026, DEA formally published a scheduling order to classify five obscure psychedelic tryptamine compounds as Schedule I substances under the Controlled Substances Act (CSA), sparking immediate backlash from legal experts, researchers and mental health advocates.
The scheduling order marks DEA’s second attempt to criminalize these specific compounds, following a heavily criticized effort that the agency was forced to withdraw in 2022. The renewed push highlights a potential fracture between federal agencies regarding the therapeutic viability of psychedelic substances, with DEA aggressively pursuing prohibition while FDA increasingly supports clinical exploration.
The compounds targeted in the DEA’s latest filing are 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET) and N,N-Diisopropyltryptamine (DiPT).
Currently unscheduled under U.S. federal law, these tryptamines belong to a class of psychedelics known for their
Read full article on Marijuana Moment
